Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
67 hedge funds and large institutions have $7M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 20 increasing their positions, 9 reducing their positions, and 16 closing their positions.
762% more call options, than puts
Call options by funds: $181K | Put options by funds: $21K
122% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 9
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
1% less funds holding
Funds holding: 68 → 67 (-1)
74% less capital invested
Capital invested by funds: $27.1M → $7M (-$20.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$13.2M |
| 2 |
WE
Wealth Effects
Boston,
Massachusetts
|
+$2.21M |
| 3 |
GJL
Gendell Jeffrey L
|
+$1.76M |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$707K |
| 5 |
MWM
Modera Wealth Management
Westwood,
New Jersey
|
+$394K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UIC
Uniplan Investment Counsel
Milwaukee,
Wisconsin
|
-$1.34M |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$935K |
| 3 |
EWA
EP Wealth Advisors
Torrance,
California
|
-$206K |
| 4 |
Millennium Management
New York
|
-$184K |
| 5 |
Mirae Asset Global Investments
Seoul,
South Korea
|
-$141K |
SEEL Hedge Fund Activity: Q3 2023 in Review
67 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q3 2023, worth a combined $7M — down 74% from $27.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SEEL and 15 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 20 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $13.2M. The largest seller was Uniplan Investment Counsel, exiting entirely with an estimated $1.34M sold.
- 67 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q3 2023, down from 68 in Q2 2023.
- Funds reported $7M of Seelos Therapeutics, Inc. Common Stock stock for Q3 2023, down 74% quarter-over-quarter.
- 15 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q3 2023 and 16 closed out, a net change of -1 holder.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q3 2023 was Sabby Management, an estimated $13.2M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q3 2023 was Uniplan Investment Counsel, an estimated $1.34M sold.
Based on aggregated 13F filings for Q3 2023.